Mark Bamforth is the President and CEO of Gallus Biopharmaceuticals. Mark founded Gallus in 2010 in order to establish the premier contract manufacturer (CMO) of clinical and commercial bulk biologics. In May 2011, he completed the purchase of an established USA facility from J&J, with a team of 160 that continues to deliver two commercial products for J&J's supply to over 75 countries. Mark grew this team to over 250 with the signing of new clients for process development and clinical supply. In Sept. 2013, Gallus acquired another CMO, Laureate Biopharma, with a strong technical pedigree and broad client base, thus adding clients and molecules to continue to grow Gallus. This expanded the Gallus team to over 350.
In this leadership role, Mark draws upon his 22 years of experience with Genzyme Corporation. During this time, Mark assembled talented teams to build and operate twelve manufacturing plants around the world, oversaw a pharmaceutical materials CMO business and served as a Corporate Officer.
Prior, Mark was a chemical engineer in the Scottish whisky industry where he led a JV biotech project to produce a nutraceutical from algae and designed, patented and operated a photo-bioreactor.
Mark began his career exploring and producing oil in the hostile waters of the North Sea.
Mark serves on the MassBio Board, representing the biotech industry in MA. Mark is a Founding Trustee of a charity, the Saltire Foundation, which offers young Scottish entrepreneurs the opportunity to experience and learn in high growth companies in the USA and beyond and to take these experiences and ambition back to Scotland.
Mark has a BS in Chemical Engineering from Strathclyde University, Glasgow, and an MBA from Henley Business School. Mark lives in MA with his wife, Morag, and their two children.